Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

1 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a new treatment called DF1001 in patients with advanced solid tumors. Solid tumors are abnormal masses of tissue that can occur in various parts of the body and may be difficult to remove or treat. The study aims to understand how safe and tolerable DF1001 is when used alone or in combination with other treatments, such as nivolumab and nab-paclitaxel. Nivolumab is a medication that helps the immune system fight cancer, while nab-paclitaxel is a form of chemotherapy that targets cancer cells. The study will also explore the effects of combining DF1001 with another drug called sacituzumab govitecan.

The purpose of this study is to find the most effective and safe dose of DF1001 for treating these tumors. Participants will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will be conducted in several parts, starting with a dose escalation phase to determine the safest dose, followed by an exploratory phase to assess the treatment’s effectiveness. The final phase will expand the study to include more patients to confirm the results.

Throughout the study, researchers will monitor participants closely to observe any side effects and measure how well the tumors respond to the treatment. The goal is to gather information that could lead to new treatment options for patients with advanced solid tumors. This study is an important step in understanding how DF1001 and its combinations can potentially improve outcomes for patients with these challenging conditions.

1 joining the study

Upon joining the study, the patient provides a signed written informed consent.

Eligibility is confirmed based on criteria such as age (18 years or older), performance status, and adequate organ function.

2 initial assessment

The patient undergoes a baseline assessment, which includes measuring the disease using specific criteria and evaluating heart function through echocardiography or a MUGA scan.

3 dose escalation phase

The patient receives DF1001 as a monotherapy or in combination with nivolumab or nab-paclitaxel through intravenous infusion.

The goal is to determine the maximum tolerated dose and assess safety and tolerability over the first 21 days.

4 exploratory efficacy phase

The patient may receive DF1001 alone or with sacituzumab govitecan to evaluate the response rate and further assess safety.

Regular monitoring of adverse events and treatment effects is conducted.

5 efficacy expansion phase

The patient continues treatment to confirm the response rate according to specific evaluation criteria.

Ongoing assessments include physical exams, vital signs, and laboratory tests.

6 completion of treatment

The study is estimated to conclude by October 2026, with follow-up assessments to monitor long-term outcomes and any late-emerging effects.

Who Can Join the Study?

You must sign a written informed consent form, which means you agree to participate in the study after being informed about it.
You must be a male or female aged 18 years or older.
You need to have an ECOG performance status of 0 to 1. This is a scale that measures your ability to perform daily activities, with 0 being fully active and 1 being restricted in physically strenuous activity but able to carry out light work.
Your disease must be measurable with at least one measurable lesion, which is a specific area of the tumor that can be measured to track changes.
Your baseline LVEF (Left Ventricular Ejection Fraction) must be 55% or higher. This is a measure of how well your heart is pumping blood.
You must have adequate blood cell counts, which means having enough white blood cells, neutrophils, lymphocytes, and platelets, as well as a stable hemoglobin level.
Your liver function must be adequate, meaning your bilirubin level should be 1.5 times the normal limit or lower, and your AST and ALT levels should be 2.5 times the normal limit or lower, unless you have liver disease, in which case they can be up to 5 times the normal limit.
Your kidney function must be adequate, with a creatinine clearance of 50 mL/min or higher. This measures how well your kidneys are filtering waste from your blood.
If you are of childbearing potential, you must agree to use effective contraception methods during the study and for a specified period after the last dose. Men must use condoms during treatment and for a period after the last dose.

Who Cannot Join the Study?

Patients who have a different type of cancer than the ones being studied.
Patients who have not recovered from previous treatments or surgeries.
Patients who have other serious health conditions that could interfere with the study.
Patients who are pregnant or breastfeeding.
Patients who are participating in another clinical trial at the same time.
Patients who have had an allergic reaction to similar treatments in the past.
Patients who are unable to follow the study procedures or attend required visits.
Patients who have a history of substance abuse that could affect their participation.
Patients who have certain infections that are not well controlled.
Patients who have received certain medications recently that could interfere with the study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Oncopole Claudius Regaud	Toulouse	France
Centr Georges Francois Leclerc	Dijon	France
Centre Hospitalier Universitaire De Bordeaux	Bordeaux	France
University Hospital Maastricht	Maastricht	The Netherlands

Other Sites

Site Name	City	Country
Hopitaux Universitaires Pitie Salpetriere	Paris	France
Centre hospitalier universitaire de Liege	Liege	Belgium
Grand Hopital De Charleroi	Charleroi	Belgium
Hopital De Libramont	Libramont-Chevigny	Belgium
Universitair Medisch Centrum Utrecht	Utrecht	The Netherlands
Stichting Radboud University Medical Center	Nijmegen	The Netherlands
Centre Hospitalier Universitaire De Rennes	Rennes	France
Rigshospitalet	Copenhagen	Denmark
Institut de Cancérologie de l’Ouest	Saint-Herblain	France
Ihmdgmcc Rauedndz Dm Cqefet Dc Mrakbyiyvjt	Montpellier	France
Cyefdc Lija Bqluvm	Lyon	France
Ujhyzdcxfjrz Mvmsktv Cwjhbcx Giwqhzsqa	Groningen	The Netherlands
Hykvzy Hvnpuhrl	Herlev	Denmark
Aqfimjuvd Ucr	Amsterdam	The Netherlands
Eobgupb Uhruvpmgpiam Mwviowt Cbeayiv Rjoayhren (qfdxoil Mmv	Rotterdam	The Netherlands
Iqcqthxc Pqkxgpksxkyycvo Cqfuqm Cxbowj	Marseille	France
Cmtbbt Omzkh Lizijlq	Lille	France
Immjbrpi Ccrrs	Paris	France

Trial status

Country	Status	Recruitment Start
Belgium	Not recruiting	22.10.2019
Denmark	Not recruiting	22.10.2019
France	Not recruiting	22.10.2019
The Netherlands	Not recruiting	22.10.2019

Trial locations

Investigated drugs:

DF1001 is an experimental medication being tested for its safety and effectiveness in treating patients with advanced solid tumors. The study aims to find the highest dose of DF1001 that patients can tolerate without severe side effects. It is being tested both as a standalone treatment and in combination with other medications.

Nivolumab is a medication that helps the immune system recognize and attack cancer cells. In this trial, it is used in combination with DF1001 to see if the two medications together can improve treatment outcomes for patients with advanced solid tumors.

Nab-paclitaxel is a chemotherapy drug that works by stopping cancer cells from dividing and growing. It is being combined with DF1001 in this study to evaluate if the combination is more effective than DF1001 alone in treating advanced solid tumors.

Sacituzumab govitecan-hziy is a targeted therapy that delivers chemotherapy directly to cancer cells. In this trial, it is combined with DF1001 to explore if this combination can enhance the treatment’s effectiveness against advanced solid tumors.

Investigated diseases:

Neoplasm

Locally Advanced or Metastatic Solid Tumors – These are cancers that have spread beyond their original site to nearby tissues or distant parts of the body. They are characterized by the growth of abnormal cells that form a mass or lump, which can invade surrounding tissues. As the disease progresses, it can spread to other organs through the bloodstream or lymphatic system. The symptoms and progression depend on the type of tumor and the organs affected. These tumors can cause pain, swelling, and other symptoms related to the affected area. The progression can vary widely, with some tumors growing slowly and others spreading rapidly.

Trial ID:

2023-503291-24-00

Protocol code:

DF1001-001

NCT ID:

NCT04143711

Trial Phase:

Human Pharmacology (Phase I) – Other

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?